Top 3 Health Care Stocks That May Collapse This Quarter
Top 3 Health Care Stocks That May Collapse This Quarter
As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
截至2024年12月11日，醫療保健行業的三隻股票可能會向將動量視爲交易決策關鍵標準的投資者發出真正的警告。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.
RSI是一個動量指標，它比較股票在價格上漲的日子裏的走強與價格下跌的日子的走強。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數高於70時，資產通常被視爲超買。
Here's the latest list of major overbought players in this sector.
以下是該行業主要超買參與者的最新名單。
Adaptive Biotechnologies Corp (NASDAQ:ADPT)
自適應生物技術公司（納斯達克股票代碼：ADPT）
- On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in guiding blood cancer treatment decisions. The company's shares gained around 6% over the past month and has a 52-week high of $7.07.
- RSI Value: 75.83
- ADPT Price Action: Shares of Adaptive Biotechnologies gained 4.2% to close at $6.71 on Tuesday.
- 12月7日，自適應生物技術在ASH 2024上公佈了新數據，展示了ClonoSeq MRD測試的進展及其在指導血液癌治療決策中的作用。該公司的股價在過去一個月中上漲了約6％，創下52周高點7.07美元。
- RSI 值：75.83
- AdpT價格走勢：自適應生物技術股價週二上漲4.2％，收於6.71美元。
NewAmsterdam Pharma Company NV (NASDAQ:NAMS)
內華達州新阿姆斯特丹製藥公司（納斯達克股票代碼：NAMS）
- On Dec. 10, NewAmsterdam Pharma revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The company's stock gained around 30% over the past five days and has a 52-week high of $26.36.
- RSI Value: 81.17
- NAMS Price Action: Shares of NewAmsterdam Pharma jumped 41.4% to close at $26.19 on Tuesday.
- 12月10日，新阿姆斯特丹製藥公司公佈了百老匯三期臨床試驗的主要數據，該試驗評估了奧比曲匹治療動脈粥樣硬化性心血管疾病（ASCVD）和/或雜合子家族性高膽固醇血癥（HeFH）的成年患者，儘管接受了最大耐受性的降脂療法，但其低密度脂蛋白仍未得到充分控制。該公司的股票在過去五天中上漲了約30％，創下52周高點26.36美元。
- RSI 值：81.17
- NAMS價格走勢：週二，新阿姆斯特丹製藥公司的股價上漲41.4％，收於26.19美元。
Paragon 28 Inc (NYSE:FNA)
Paragon 28 Inc（紐約證券交易所代碼：FNA）
- On Nov. 12, Paragon 28 reported quarterly losses of 15 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $62.30 million which beat the analyst consensus estimate of $60.58 million. The company's stock gained around 38% over the past month and has a 52-week high of $14.79.
- RSI Value: 77.07
- FNA Price Action: Shares of Paragon 28 gained 5% to close at $10.50 on Tuesday.
- 11月12日，Paragon 28公佈的季度虧損爲每股15美分，符合分析師的共識預期。該公司公佈的季度銷售額爲6,230萬美元，超過了分析師普遍預期的6,058萬美元。該公司的股票在過去一個月中上漲了約38％，創下了52周高點14.79美元。
- RSI 值：77.07
- FNA價格走勢：百麗宮28股價週二上漲5％，收於10.50美元。
Read This Next:
接下來閱讀這篇文章：
- Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear & Greed Index Remains In 'Neutral' Zone
- 道瓊斯指數連續第四個交易日下跌，谷歌量子芯片宣佈後Alphabet飆升：恐懼與貪婪指數仍處於 「中立」 區域
譯文內容由第三人軟體翻譯。
